<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1744">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378920</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003</org_study_id>
    <secondary_id>2020-001393-30</secondary_id>
    <secondary_id>2020-A00900-39</secondary_id>
    <nct_id>NCT04378920</nct_id>
  </id_info>
  <brief_title>A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715)</brief_title>
  <acronym>LEAF-4L6715</acronym>
  <official_title>A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancerologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEAF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancerologie Strasbourg Europe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase II study of treatment with LEAF-4L7520 and LEAF-4L6715 in
      patients who experience severe acute respiratory distress syndrome (ARDS) and are receiving
      artificial respiratory support due to COVID-19. The purpose of this study is to evaluate the
      improvement in PaO2/FiO2 by more than 25% in two cohorts of patients treated with LEAF-4L7520
      or LEAF-4L6715.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first cohort, patients will be enrolled to receive LEAF-4L7520 at a dose of 0.25 mg/kg
      administered as intravenous (IV) bolus every 3 hours.

      The second cohort is treated by and LEAF-4L6715, a liposomal formulation containing trans
      crocetin. The liposomal formulation allows for a gradual release of the free drug, thereby
      facilitating once a day or less frequent dosing.

      Pharmacokinetic assessment will be carried out to identify an optimal dose and schedule.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>COVID19</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>4L6715</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 : a dose of 5 mg/kg/day Day 2 and other : a dose of 2.5 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4L7520</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose 0.25 mg/kg bolus every 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEAF-4L6715</intervention_name>
    <description>LEAF-4L6715</description>
    <arm_group_label>4L6715</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEAF-4L7520</intervention_name>
    <description>LEAF-4L7520</description>
    <arm_group_label>4L7520</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent from the patient or patient's legal representative must be
             obtained prior to any procedures, as the likelihood of patients being able to provide
             consent is very limited

          2. Patients must be ≥ 18 years old

          3. Patient must be test positive for COVID-19 infection and/or have a pathognomonic CT
             scan

          4. Patient must have acute respiratory distress syndrome as defined, with a PaO2/FiO2
             ratio of less than 200 mm Hg (supplementary method file 1)

          5. Patient must be under artificial ventilation support

          6. Patient must have a life expectancy of at least 24 hours

          7. Patients should have normal liver function as defined by ALT, AST and alkaline
             phosphate less than 3 ULN for the institution

          8. Patient must have platelet count above &gt;100,000 cells/mm3, hemoglobin &gt; 8 g/dL and an
             absolute neutrophil count (ANC) of &gt; 1000 cells/mm3

          9. Patients should have normal renal function as defined by creatinine clearance of 50
             ml/min or higher

        Exclusion Criteria:

          1. Patient is enrolled in any other therapeutic clinical trial with the same endpoints.
             All observational studies or study with limited invasive methods (Pharmacokinetic
             studies, monitoring of virus charges studies, biological monitoring studies ….) are
             allowed

          2. Patient is pregnant or breast-feeding

          3. Patient has a known hypersensitivity to crocetins, LEAF-4L7520, LEAF-4L6715 or any of
             its excipients

          4. Patients with hemoglobinopathy

          5. Patients receiving extracorporeal membrane oxygenation (ECMO)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valerie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN, PhD</last_name>
    <phone>368767360</phone>
    <phone_ext>33</phone_ext>
    <email>m.voegelin@icans.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Michel MERTES, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier COLLANGE, PhD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Vitaliy CHABAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

